Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that testosterone-enanthate increased red blood cell production and altered iron homeostasis in older hypogonadal men without being affected by finasteride, indicating these effects do not require type II 5α-reductase enzyme activity.

Using testosterone-stimulated weanling rats can effectively replace castrated rats for anti-androgen testing, reducing animal stress.

This study found that obesity in PCOS women with biochemical hyperandrogenemia lowers androstenedione levels and increases the testosterone to androstenedione ratio, but this was not observed in women with clinical hyperandrogenemia or in controls.

This research suggests that the enzyme Phospholipase D from E. coli is a strong candidate as the underlying cause of benign prostatic hyperplasia, potentially mediated by its conversion to lysophosphatidic acid in the prostate.

In this case report, the researchers emphasize the importance of regular prostate exams and PSA tests for diabetic men, including those who are hypogonadal, because prostate cancer development is linked to intraprostatic dihydrotestosterone levels, not serum testosterone levels.

This study found that LHE may prevent and reverse testosterone-induced prostatic hyperplasia, supporting the traditional use of Kigelia africana for some reproductive system disorders.

In this study, 1'-S-1'-acetoxychavicol acetate (ACA) from Alpinia galanga showed potential in suppressing testosterone-induced hair loss by inhibiting Nox isozymes in a mouse model of androgenetic alopecia.

In this study, researchers investigated the effects of Aqueous Artocarpus heterophyllus seed extract on testosterone enanthate-induced benign prostatic hyperplasia in adult Wistar rats, using three different dosages to assess its potential as an alternative therapy. Results are not reported in this abstract.

This abstract reviews testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production and reports no new research findings.

This study investigated various compounds inhibiting testosterone 5alpha-reductase for potential treatment of benign prostatic hyperplasia, finding that heparin and progesterone demonstrated inhibitory effects under specific conditions.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

In this placebo-controlled study, finasteride significantly improved symptoms, reduced prostate size, and increased urine flow rate in patients with moderately symptomatic BPH over two years.

This review discusses 46,XY disorders of sex development caused by defects in androgen production and highlights the need for long-term care from experienced multidisciplinary teams, but it reports no new clinical findings.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This article discusses the enzyme pathways involved in androgenetic alopecia and the role of finasteride in reducing dihydrotestosterone levels to promote hair growth; it reports no new clinical results.

Finasteride helps treat male hair loss but may lower sex drive.

This research outlines that antiandrogens have mechanisms involving competitive inhibition of androgen binding and enzyme inhibition, with contraindications during pregnancy due to potential fetal risks.

This study found that in male mouse pancreatic islet β cells, testosterone enhances glucose-stimulated insulin secretion by being locally converted into dihydrotestosterone and estradiol.

This study found that several new pregnane derivatives, especially steroids 16 and 19, demonstrated higher antiandrogenic activity on male hamster models than the commonly used finasteride.

This review concluded that 5α-reductase inhibitors like finasteride and dutasteride offer limited additional feminising effects in hormone therapy for transfeminine individuals, with the clearest use being androgenetic alopecia treatment; more research is needed for other potential benefits.

This study reviewed early research on topical finasteride for androgenetic alopecia, finding it appears safe and promising, though further investigation is needed to determine optimal dosing, frequency, and potential applications for other types of alopecia.

This review discusses caffeine's potential role in treating androgenetic alopecia by counteracting DHT effects on hair follicles and enhancing cell proliferation, but reports no new clinical results.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This study found that prenatal exposure to finasteride in rats led to permanent changes in developmental endpoints like anogenital distance and nipple retention, which were predictive of further reproductive tract malformations.

This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.

This article reviews the use of finasteride for treating male pattern hair loss, highlighting its mechanism of action in reducing DHT and noting its safety profile with some common adverse effects.

This review found that women with idiopathic hirsutism may have increased 5α-reductase activity, as indicated by elevated levels of a dihydrotestosterone-reduced metabolite, but more research is needed to confirm its clinical relevance as a biomarker.

Finasteride increases hair density in female androgenetic alopecia, but individual results may vary.

This study reported that while finasteride and progesterone significantly inhibited dihydrotestosterone synthesis in dermal papillae, estrogens were less effective.